The U.S. Food and Drug Administration (FDA) has granted VERO Biotech an “expanded access emergency use” allowing its proprietary inhaled nitric oxide (iNO) delivery system, Genosyl DS, to immediately be used for the treatment of cardiopulmonary symptoms associated with COVID-19. Genosyl (nitric oxide) gas, for inhalation, was recently approved by FDA for the treatment of persistent pulmonary hypertension of the newborn (PPHN) and is the only tankless inhaled nitric oxide device avail...